The comorbidity of papillary thyroid carcinoma and the primary hyperparathyroidism

Skrócona strona pozycji
dc.contributor.authorPodlasek, Robert
dc.contributor.authorBednarczyk, Grzegorz
dc.contributor.authorŚwider, Grzegorz
dc.date.accessioned2018-09-24T08:41:11Z
dc.date.available2018-09-24T08:41:11Z
dc.date.issued2018
dc.description.abstractIntroduction. The prevalence of papillary thyroid carcinoma (PTC) in patients with primary hyperparathyroidism (PHPT) is low, it can be estimated around 2 to 4%. For unknown reasons it is higher than the prevalence of PTC in the overall population. The authors analyse the comorbidity of PTC with PHPT on patients treated in their institution. Material and method. The analysis covered medical records of 885 patients subject to the thyroid resection procedure and 95 patients operated for PHPT, the procedures were performed in years 2005-2014. Results. In the above-mentioned period there were 121 patients operated due to a malignant thyroid tumour and there were 95 patients that had surgery for PHPT. There were 4 cases of comorbidity of PHPT with papillary thyroid cancer. Prevalence of PTC at the patients with PHPT was 4.2%. In two out of the four cases, both diseases were diagnosed prior to the procedure and the single appropriate surgery i.e. total thyroidectomy and excision of parathyroid adenoma was performed. In the other two cases false positive localisation of parathyroid adenoma occurred due to metastatic cancerous lesions in cervical lymph nodes. The diagnosis of PTC was made postoperatively based on surgical specimen examination. Second surgical procedure appropriate for this diagnosis was necessary in both cases. Conclusions. The comorbidity of PHPT and PTC is clinically important and should be taken into account in the case of patients with PHPT and thyroid tumours. There is the possibility of false positive localization of parathyroid adenoma in the case of metastatic cancerous lesions in cervical lymph nodes.pl_PL.UTF-8
dc.identifier.citationEuropean Journal of Clinical and Experimental Medicine T. 16, z. 2 (2018), s. 103–108pl_PL.UTF-8
dc.identifier.doi10.15584/ejcem.2018.2.4
dc.identifier.eissn2544-1361
dc.identifier.issn2544-2406
dc.identifier.urihttp://repozytorium.ur.edu.pl/handle/item/3889
dc.language.isoengpl_PL.UTF-8
dc.publisherWydawnictwo Uniwersytetu Rzeszowskiegopl_PL.UTF-8
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Międzynarodowe*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectthyroid carcinomapl_PL.UTF-8
dc.subjectprimary hyperparathyroidismpl_PL.UTF-8
dc.subjectparathyroid adenomapl_PL.UTF-8
dc.titleThe comorbidity of papillary thyroid carcinoma and the primary hyperparathyroidismpl_PL.UTF-8
dc.typearticlepl_PL.UTF-8
Pliki
Oryginalny pakiet
Aktualnie wyświetlane 1 - 1 z 1
Obrazek miniatury
Nazwa:
4 podlasek-the comorbidity.pdf
Rozmiar:
143.94 KB
Format:
Adobe Portable Document Format
Opis:
Pobierz
Pakiet licencji
Aktualnie wyświetlane 1 - 1 z 1
Obrazek miniatury
Nazwa:
license.txt
Rozmiar:
1.22 KB
Format:
Item-specific license agreed upon to submission
Opis:
Pobierz
Kolekcje
European Journal of Clinical and Experimental Medicine T.16, z. 2 (2018)